EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Slides:

Advertisements

Similar presentations

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA Tomomi Nakamura, MD, Naoko.

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Detection of Exon 12 Mutations in the JAK2 Gene

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients Antonio Marchetti, MD, PhD,

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer Suzanne Jenkins, DPhil, James C-H.

Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and.

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Geoffrey R. Oxnard, MD, Vincent A. Miller, MD, Mark E

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients Clotilde Descarpentries, PharmD, Frédéric Leprêtre, PhD, Fabienne.

Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases Yi-Lin Chen, Cheng-Chan Lu, Shu-Ching.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non– Small Cell Lung Cancer Kazuko Sakai, PhD, Isamu Okamoto, MD, PhD, Ken Takezawa,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Activity of Gefitinib in a Non–Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations Alessandro Morabito, MD, Raffaele Costanzo,

Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Role of Chromosome 3q Amplification in Lung Cancer

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer Soyeon Kim, PhD, Tae Min Kim, MD, PhD,

Erratum Journal of Thoracic Oncology

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA Tomomi Nakamura, MD, Naoko.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas Qiulu Pan, William Pao, Marc.

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers Ryoichi Onozato, MD,

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin Chan, PhD, James Chung-Man Ho, MD, Mary Ip, MD, Wah-Kit Lam, MD, Tai-Kwong Chan, MD, Vivian Chan, PhD Journal of Thoracic Oncology Volume 7, Issue 7, Pages 1131-1140 (July 2012) DOI: 10.1097/JTO.0b013e3182558198 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Sensitivity experiment showing the detection of A-PCR products of exon 21 of the EGFR gene prepared from (A) equal amounts (100,000 copies) of cloned L858R mutant (mt) and wild-type (wt, from 300 ng normal genomic DNA), (B) 5000 copies L858R mt in the presence of wt, (C) 62.5 copies L858R mt in the presence of wt, and (D) 31 copies L858R mt in the presence of wt. Each panel shows a section of the array where oligonucleotide primers for detecting mutations in Exon 20 and Exon 21 of the EGFR gene are spotted. Primers are spotted twice, in triplicate rows. Wt = primers for wild type sequence and mt = primer for mutant sequence. The codon position of these sequences along the gene is indicated at the top of each panel. Note that fluorescent signal intensity is white > red > yellow > green, with blue as background. B, Sensitivity experiment showing the detection of A-PCR products of exon 18 of the EGFR gene prepared from (A) equal amounts (10,000) copies of cloned E709K + G719A mt and wt (from 30 ng normal genomic DNA), (B) 31 copies of the same Exon 18 mt and 10,000 copies wt, (C) equal amounts (10,000 copies) of cloned Exon 19 del 746-50 mt and wt (30 ng genomic DNA), and (D) 125 copies Exon 19 mt in the presence of 10,000 copies wt. A-PCR, asymmetric PCR; EGFR, epidermal growth factor receptor; mt, mutant; wt, wild type. Journal of Thoracic Oncology 2012 7, 1131-1140DOI: (10.1097/JTO.0b013e3182558198) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Results of plasma-DNA analysis in a patient with NSCLC (TKL001), during 40 months’ longitudinal follow-up. Primers for detecting drug-resistant mutations are located at the right of each panel. NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2012 7, 1131-1140DOI: (10.1097/JTO.0b013e3182558198) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions